As more Americans try to get their hands on the prescription medication Wegovy while they try to shed significant amounts of weight, an even more powerful obesity drug is poised to enter the fray. On Thursday, drug maker Eli Lilly & Co. announced that its type 2 diabetes drug tirzepatide (Mounjaro) helped people with diabetes who were overweight or obese lose nearly 16% of their body weight, or more than 34 pounds, over 17 months. This late-stage study of the drug adds to earlier evidence published last summer in the New England Journal of Medicine that showed overweight or obese people without diabetes lost up to 22% of their body weight over that period with weekly injections of the drug. For a typical patient on the highest dose, that meant shedding more than 50 pounds. Results from both studies will now be part of the company’s application to the U.S. Food and Drug Administration for fast-track approval of the drug for weight loss. “We have not hit 15% in any other phase 3 trial for weight management in this type 2 diabetes population,” Dr. Nadia Ahmad, an associate vice president at Eli Lilly and medical director of obesity clinical development for the company, told CNN. Importantly, this data has not yet been peer-reviewed or published in a medical journal. “In the last year, [it] has… read on > read on >

















